Factor Xa inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Factor Xa inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Factor Xa inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Factor Xa inhibitors: Overview
Inhibition of clotting factor Xa has been evaluated as a potential target for anticoagulation therapy with the hypothesis that using target-specific therapy will alleviate some of the dosing variability observed with the vitamin K antagonist. The FXa inhibitors have a unique mechanism of action compared with the VKA historically used for oral anticoagulation. FXa is common to both the intrinsic and extrinsic pathways of the clotting cascade making it an excellent target for anticoagulation therapy. It plays a significant role in the formation of thrombin from prothrombin. A single molecule of Xa leads to the creation of 1000 molecules of thrombin. Inhibition of Xa leads to a significant reduction in thrombin and ultimately clot formation
All of the currently available FXa inhibitors are contraindicated for use in patients experiencing active bleeding. In addition, they all carry United States (US) Black Boxed Warnings for premature discontinuation and spinal/epidural hematomas. The risk for ischemic events increases when FXa inhibitors are discontinued without an adequate alternative oral or parenteral anticoagulant in place. There is also a risk for the development of spinal/epidural hematomas when FXa inhibitors are used in patients undergoing spinal procedures including neuroaxial anesthesia and spinal puncture.
Currently available FXa inhibitors have been shown to be noninferior to warfarin with regards to efficacy and safety in clinical trials and are viable treatment options for patients with nonvalvular atrial fibrillation.
Report Highlights
This segment of the Factor Xa inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Factor Xa inhibitors Emerging Drugs
Further product details are provided in the report……..
Factor Xa inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Factor Xa inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Factor Xa inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Factor Xa inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Factor Xa inhibitors drugs.
Factor Xa inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Factor Xa inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Factor Xa inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Factor Xa inhibitors: Overview
Inhibition of clotting factor Xa has been evaluated as a potential target for anticoagulation therapy with the hypothesis that using target-specific therapy will alleviate some of the dosing variability observed with the vitamin K antagonist. The FXa inhibitors have a unique mechanism of action compared with the VKA historically used for oral anticoagulation. FXa is common to both the intrinsic and extrinsic pathways of the clotting cascade making it an excellent target for anticoagulation therapy. It plays a significant role in the formation of thrombin from prothrombin. A single molecule of Xa leads to the creation of 1000 molecules of thrombin. Inhibition of Xa leads to a significant reduction in thrombin and ultimately clot formation
All of the currently available FXa inhibitors are contraindicated for use in patients experiencing active bleeding. In addition, they all carry United States (US) Black Boxed Warnings for premature discontinuation and spinal/epidural hematomas. The risk for ischemic events increases when FXa inhibitors are discontinued without an adequate alternative oral or parenteral anticoagulant in place. There is also a risk for the development of spinal/epidural hematomas when FXa inhibitors are used in patients undergoing spinal procedures including neuroaxial anesthesia and spinal puncture.
Currently available FXa inhibitors have been shown to be noninferior to warfarin with regards to efficacy and safety in clinical trials and are viable treatment options for patients with nonvalvular atrial fibrillation.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Factor Xa inhibitors R&D. The therapies under development are focused on novel approaches for Factor Xa inhibitors.
This segment of the Factor Xa inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Factor Xa inhibitors Emerging Drugs
- Rivaroxaban: Bayer
Further product details are provided in the report……..
Factor Xa inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Factor Xa inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Factor Xa inhibitors
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Factor Xa inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Factor Xa inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Factor Xa inhibitors drugs.
Factor Xa inhibitors Report Insights
- Factor Xa inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Factor Xa inhibitors drugs?
- How many Factor Xa inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Factor Xa inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Factor Xa inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Factor Xa inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Chong Kun Dang Pharmaceutical
- Carbomimetics
- CSPC ZhongQi Pharmaceutical Technology
- Bayer
- AMAG Pharmaceuticals
- Pfizer
- CKD-344
- CM20201
- SYHA-136
- Rivaroxaban
- Ciraparantag
- PF-05230907
Introduction
Executive Summary
Factor Xa inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Factor Xa inhibitors– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Factor Xa inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Factor Xa inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Rivaroxaban: Bayer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CKD-344: Chong Kun Dang Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
CM20201: Carbomimetics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Factor Xa inhibitors Key Companies
Factor Xa inhibitors Key Products
Factor Xa inhibitors- Unmet Needs
Factor Xa inhibitors- Market Drivers and Barriers
Factor Xa inhibitors- Future Perspectives and Conclusion
Factor Xa inhibitors Analyst Views
Factor Xa inhibitors Key Companies
Appendix
Executive Summary
Factor Xa inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Factor Xa inhibitors– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Factor Xa inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Factor Xa inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Rivaroxaban: Bayer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CKD-344: Chong Kun Dang Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
CM20201: Carbomimetics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Factor Xa inhibitors Key Companies
Factor Xa inhibitors Key Products
Factor Xa inhibitors- Unmet Needs
Factor Xa inhibitors- Market Drivers and Barriers
Factor Xa inhibitors- Future Perspectives and Conclusion
Factor Xa inhibitors Analyst Views
Factor Xa inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Factor Xa inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Factor Xa inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Factor Xa inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Factor Xa inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
